WASHINGTON UNIVERSITY SCHOOL OF MEDICINE
News & Events
Maps & Locations
PATIENT AND VISITOR INFORMATION
PREVENTION AND SCREENING
HOW TO HELP
FOR HEALTH PROFESSIONALS
Go back to:
Content Block Control
RETURN TO SEARCH RESULTS
Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma
You may be invited to participate in a research study to treat non-Hodgkin’s lymphoma. The treatment plan consists of an autologous hematopoietic (blood) cell transplant followed by a non-myeloablative allogeneic transplantation (transplant from another individual). An autologous transplant is done using your own hematopoietic cells.
The non-myeloablative transplant is being done after the autologous transplant to try and improve the chances for long-term control of lymphoma.
The purpose of this study is to collect information on the possibility of patient’s disease returning or becoming worse and side effects of the treatment. Routinely patients receive an autologous transplant and if they relapse they may also receive an allogeneic transplant. The investigational part of this study is the timing of the two treatments in patients with high risk of relapse.
(Links will take you off this web site)
Internal Protocol Documents (requires Siteman administrative database password)
© 2009 All rights reserved